Results 161 to 170 of about 19,808 (220)

Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma [PDF]

, 2019
Berta, András, Block, Norman L., Buglyó, Armin, Dezső, Balázs, Gardi, János, Halmos, Gábor, Molnár-Fodor, Klára, Oláh, Gábor, Rózsa, Bernadett, Schally, Andrew V., Steiber, Zita, Treszl, Andrea   +11 more
core  

Predictive factors for persistent thrombocytopenia after peptide receptor radioligand therapy in enteropancreatic neuroendocrine tumors. [PDF]

Front Endocrinol (Lausanne)
Ferrara R, Zemmour C, Reichert T, Ouk D, Niccoli P, Maniry-Quellier J, Brenot-Rossi I, Charrier N, Oziel-Taieb S.   +8 more
europepmc   +1 more source

Development of a CT-less SPECT Acquisition Protocol for Kidney Dosimetry in ¹⁷⁷Lu-PSMA-617 Radioligand Therapy. [PDF]

Mol Imaging Biol
Happel C, Völler L, Bockisch B, Groener D, Leonhäuser B, Grünwald F, Sabet A.   +6 more
europepmc   +1 more source

Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopenia. [PDF]

Eur J Nucl Med Mol Imaging
Bastian MB, Sieben M, Blickle A, Burgard C, Speicher T, Bartholomä M, Schaefer-Schuler A, Maus S, Ezziddin S, Rosar F.   +9 more
europepmc   +1 more source

Genomic instability is associated with response to [¹⁷⁷Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysis. [PDF]

Eur J Nucl Med Mol Imaging
Kluge K, Haberl D, Haug A, Kenner L, Kramer G, Shariat S, Kumpf K, Hacker M.   +7 more
europepmc   +1 more source

Cancer-control outcomes with [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patients. [PDF]

Theranostics
Wenzel M, Siech C, Garcia CC, Humke C, Groener D, Kriegmair M, Graefen M, Maurer T, Salomon G, Banek S, Chun FKH, Mandel P.   +11 more
europepmc   +1 more source

Bellmunt risk score enables survival prediction in men with metastatic castration resistant prostate cancer (mCRPC) undergoing PSMA-targeted radioligand therapy (LUMEN). [PDF]

Eur J Nucl Med Mol Imaging
Büttner T, Marinova M, Gaertner FC, Kreppel B, Fritsche L, Immanuel C, Geraths G, Kürpig S, Küppers J, Schmidt-Wolf IGH, Essler M, Ritter M, Krausewitz P.   +12 more
europepmc   +1 more source

AI-driven body composition monitoring and its prognostic role in mCRPC undergoing lutetium-177 PSMA radioligand therapy: insights from a retrospective single-center analysis. [PDF]

EJNMMI Res
Ruhwedel T, Rogasch J, Galler M, Schatka I, Wetz C, Furth C, Biernath N, De Santis M, Shnayien S, Kolck J, Geisel D, Amthauer H, Beetz NL.   +12 more
europepmc   +1 more source

Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study. [PDF]

Eur J Nucl Med Mol Imaging
Marini I, Giunta EF, Nicolini S, Grassi I, Foca F, Sarnelli A, Di Iorio V, Vizza L, Giani E, Celli M, Monti M, Severi S, De Giorgi U, Borgia F, Paganelli G, Matteucci F, Sansovini M.   +16 more
europepmc   +1 more source

Development and evaluation of a single domain antibody targeting folate receptor alpha for radioligand therapy. [PDF]

J Nanobiotechnology
Dewulf J, Massa S, Navarro L, Dekempeneer Y, Santens F, Ceuppens H, Breckpot K, Van Ginderachter JA, Lahoutte T, D'Huyvetter M, Devoogdt N.   +10 more
europepmc   +1 more source